Shire: Clinical Trials

445 trials sponsored by Shire, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

359 completed, 51 terminated, 16 withdrawn, 9 unknown. 167 Phase 3, 88 Phase 2, 71 Phase 1, 64 Phase 4, 15 Not applicable.

By phase and status

Phase	Trials	Status
Phase 3	167	Completed 134, Terminated 23, Withdrawn 7, Active not recruiting 2, Unknown 1
Phase 2	88	Completed 74, Terminated 10, Active not recruiting 2, Withdrawn 2
Phase 1	71	Completed 65, Terminated 3, Withdrawn 2, Unknown 1
Phase 4	64	Completed 49, Terminated 8, Withdrawn 4, Unknown 2, Recruiting 1
Not applicable	15	Completed 12, Unknown 2, Terminated 1

Follow Shire: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Replagal in Children and Adults With Fabry Disease in India Replagal - Fabry Disease	Phase 4	Recruiting	Shire	5	2022-11-01	2026-09-03
A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism rhPTH(1-84) - Chronic Hypoparathyroidism	Phase 3	Withdrawn	Shire		2022-08-31	2022-10-10
Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications Teduglutide, Placebo - Ileostomy - Stoma	Phase 3	Withdrawn	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)		2022-06-02	2023-02-23
A Study of Replagal in Treatment-naïve Adults With Fabry Disease REPLAGAL - Fabry Disease	Phase 3	Terminated	Shire	17	2021-12-28	2024-06-17
Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India Gaucher Disease		Completed	Shire	21	2021-07-28	2023-06-07
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura TAK-755 - Thrombotic Thrombocytopenic Purpura (TTP)	Phase 3	Active not recruiting	Takeda	77	2021-04-14	2026-04-02
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study ARALAST NP - Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency	Phase 4	Withdrawn	Shire		2021-03-08	2020-09-14
Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID) Primary Immunodeficiencies (PID)		Completed	Shire	96	2021-02-08	2021-11-17
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Lanadelumab - Angioedema	Phase 3	Completed	Shire	73	2021-02-05	2024-06-17
A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants Teduglutide, Syringe Injection, Pen injector - Healthy Volunteers	Phase 1	Completed	Shire	64	2021-01-13	2022-10-04
CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60% Placebo saline solution, Heparin, CINRYZE - Kidney Failure	Phase 1	Unknown	University of Wisconsin, Madison	72	2020-12-01	2020-10-22
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Lanadelumab, Placebo - COVID-19 Pneumonia	Phase 1	Withdrawn	Shire		2020-10-31	2020-10-12
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants Maribavir (400 mg), Maribavir (200 mg), Maribavir (800 mg) - Healthy Volunteers	Phase 1	Completed	Shire	24	2020-08-07	2025-09-11
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) Lanadelumab - Hereditary Angioedema (HAE)	Phase 3	Completed	Shire	12	2019-12-12	2022-09-30
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II Hereditary Angioedema (HAE)		Completed	Shire	140	2019-12-11	2025-09-02
A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants Maribavir - Healthy Volunteers	Phase 1	Terminated	Shire	20	2019-10-25	2025-09-02
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease TAK-755, Placebo - Sickle Cell Disease	Phase 1	Completed	Shire	19	2019-10-21	2024-04-23
Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Placebo, SHP655, Standard of Care - Acquired Thrombotic Thrombocytopenic Purpura (aTTP)	Phase 2	Completed	Shire	28	2019-10-09	2022-12-01
A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies Gaucher Disease		Terminated	Shire	2	2019-09-19	2024-02-02
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD) Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo - Attention Deficit Hyperactivity Disorder	Phase 4	Completed	Shire	396	2019-09-18	2026-04-13

Shire: Clinical Trials

445 trials sponsored by Shire, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

By phase and status

Trials newest first · largest first

Conditions studied

Interventions

Countries

Top investigators

Results publications

NIH funding